Angiomodulators in cancer therapy: New perspectives

Lenka Varinska, Peter Kubatka, Jan Mojzis, Anthony Zulli, Katarina Gazdikova, Pavol Zubor, Dietrich Busselberg, Martin Caprnda, Radka Opatrilova, Iveta Gasparova, Martin Klabusay, Martin Pec, Eitan Fibach, Mariusz Adamek, Peter Kruzliak

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

The formation of new blood vessels plays a crucial for the development and progression of pathophysiological changes associated with a variety of disorders, including carcinogenesis. Angiogenesis inhibitors (anti-angiogenics) are an important part of treatment for some types of cancer. Some natural products isolated from marine invertebrates have revealed antiangiogenic activities, which are diverse in structure and mechanisms of action. Many preclinical studies have generated new models for further modification and optimization of anti-angiogenic substances, and new information for mechanistic studies and new anti-cancer drug candidates for clinical practice. Moreover, in the last decade it has become apparent that galectins are important regulators of tumor angiogenesis, as well as microRNA. MicroRNAs have been validated to modulate endothelial cell migration or endothelial tube organization. In the present review we summarize the current knowledge regarding the role of marine-derived natural products, galectins and microRNAs in tumor angiogenesis.

Original languageEnglish
Pages (from-to)578-590
Number of pages13
JournalBiomedicine and Pharmacotherapy
Volume89
DOIs
Publication statusPublished - 1 May 2017

    Fingerprint

Keywords

  • Angiogenesis
  • Anti-angiogenics
  • Cancer therapy
  • Galectins
  • Marine natural products
  • microRNAs

ASJC Scopus subject areas

  • Pharmacology

Cite this

Varinska, L., Kubatka, P., Mojzis, J., Zulli, A., Gazdikova, K., Zubor, P., Busselberg, D., Caprnda, M., Opatrilova, R., Gasparova, I., Klabusay, M., Pec, M., Fibach, E., Adamek, M., & Kruzliak, P. (2017). Angiomodulators in cancer therapy: New perspectives. Biomedicine and Pharmacotherapy, 89, 578-590. https://doi.org/10.1016/j.biopha.2017.02.071